India’s Sun Pharma Strikes Unique $400 Million Supply Deal To Cushion Protonix Debacle
This article was originally published in PharmAsia News
Executive Summary
India’s Sun Pharma is known for its deal-making agility. After clinching several distressed assets, Sun has now struck a unique deal that potentially shields it from the aftershocks of the $550 million setback it faced last year following the Protonix case.